| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 13:00 | NLS Pharmaceutics Ltd.; Kadimastem Ltd.: NLS Pharmaceutics and Kadimastem Highlight Continued BIRD Foundation Support for ITOL-102 Diabetes Program Following Merger | 41 | PR Newswire | ZURICH, Oct. 29, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (Nasdaq: NLSP) ("NLS" or the "Company"), a biopharmaceutical company focused on developing innovative therapies for central... ► Artikel lesen | |
| 12:00 | NLS Pharmaceutics Ltd.; Kadimastem Ltd.: NLS Pharmaceutics Ltd. Announces 1-for-10 Reverse Share Split and Name Change in Connection with Proposed Merger with Kadimastem | 46 | PR Newswire | ZURICH, Oct. 29, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (NASDAQ: NLSP) (NASDAQ: NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company... ► Artikel lesen | |
| NLS PHARMACEUTICS Aktie jetzt für 0€ handeln | |||||
| 11:30 | NLS Pharmaceutics to execute 1-for-10 reverse share split | 1 | Seeking Alpha | ||
| 09:53 | NLS Pharmaceutics Ltd.; Kadimastem Ltd.: NLS Pharmaceutics and Kadimastem Announce Completion of Material Conditions Precedent for Merger Transaction and Delisting Date of Kadimastem's Shares | 53 | PR Newswire | ZURICH and NESS ZIONA, Israel, Oct. 29, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (NASDAQ: NLSP) (NASDAQ: NLSPW) ("NLS" or the "Company") and Kadimastem Ltd. (TASE: KDST) ("Kadimastem")... ► Artikel lesen | |
| Mo | NLS Pharmaceutics Ltd.; Kadimastem Ltd.: NLS Pharmaceutics and Kadimastem Announce Strategic Collaboration between Kadimastem and TargetGene to Advance Next-Generation Gene-Edited Cell Therapies | 238 | PR Newswire | The collaboration will progress under the combined company, NewCelX, upon completion of the anticipated merger ZURICH and NESS ZIONA, Israel, Oct. 27, 2025 /PRNewswire/ -- NLS Pharmaceutics... ► Artikel lesen | |
| Do | NLS Pharmaceutics and Kadimastem merger to close Oct. 30 after Nasdaq approval | 2 | Investing.com | ||
| Do | NLS Pharmaceutics Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| Do | NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Receipt of Nasdaq Approval; Merger Expected to Close on October 30, 2025 | 1.809 | PR Newswire | ZURICH, Oct. 23, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (Nasdaq: NLSP) (Nasdaq: NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on central nervous system... ► Artikel lesen | |
| 10.10. | Fusion mit Kadimastem: NLS Pharmaceutics reicht Finanzberichte ein | 1 | Investing.com Deutsch | ||
| 10.10. | NLS Pharmaceutics Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 30.09. | NLS Pharmaceutics stock tumbles after merger approval with Kadimastem | 3 | Investing.com | ||
| 30.09. | NLS Pharmaceutics: Aktie bricht nach Fusionszustimmung mit Kadimastem ein | 1 | Investing.com Deutsch | ||
| 30.09. | Aktionäre von NLS Pharmaceutics stimmen Fusion mit Kadimastem zu | 2 | Investing.com Deutsch | ||
| 30.09. | NLS Pharmaceutics Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 30.09. | NLS Pharmaceutics Shareholders Approve Merger with Kadimastem and Related Proposals at Extraordinary General Meeting | 465 | PR Newswire | Vote clears final corporate milestone, paving the way for the closing of the merger and the combined company of NewCelX Ltd., a Nasdaq-listed biotechnology company ZURICH, Sept. 30, 2025 /PRNewswire/... ► Artikel lesen | |
| 25.09. | NLS Pharmaceutics files to sell 5M common shares for holders | 2 | Seeking Alpha | ||
| 25.09. | NLS Pharmaceutics Ltd. - F-1, Registration statement for certain foreign private issuers | 2 | SEC Filings | ||
| 19.09. | NLS Pharmaceutics Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 10.09. | Fusion von NLS Pharmaceutics und Kadimastem: SEC erteilt Freigabe | 4 | Investing.com Deutsch | ||
| 10.09. | SEC clears registration for NLS Pharmaceutics and Kadimastem merger | 1 | Investing.com |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| AVIDITY BIOSCIENCES | 69,92 | +0,01 % | Novartis kündigt die milliardenschwere Übernahme von Avidity Biosciences an, um damit das eigene Portfolio zu stärken | Bereits im Sommer wurde darüber gemunkelt, nun gibt es auch Gewissheit: Novartis übernimmt das US-Biotechunternehmen Avidity Biosciences und greift dafür tief in die Tasche. Zwölf Milliarden US-Dollar... ► Artikel lesen | |
| QIAGEN | 40,930 | -0,51 % | QIAGEN N.V.: QIAGEN Marks 4,000th QIAcube Connect Placement, Reaffirming Leadership in Automated Sample Processing | QIAcube Connect drives lab efficiency by automating critical steps in molecular biology workflows for both research and clinical customers Milestone builds on nearly 13,000 cumulative placements... ► Artikel lesen | |
| ERNEXA THERAPEUTICS | 1,820 | +46,77 % | Ernexa Therapeutics Inc.: Ernexa Therapeutics Provides Update on Operational Excellence and Performance | CAMBRIDGE, Mass., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today provided... ► Artikel lesen | |
| BIONTECH | 90,20 | -0,55 % | BioNTech startet milliardenschweres Umtauschangebot für CureVac-Aktien | BioNTech hat das öffentliche Umtauschangebot für alle ausstehenden Aktien von CureVac N.V. gestartet. Das Angebot basiert auf dem Kaufvertrag vom 12. Juni 2025 und sieht vor, dass jede CureVac-Aktie... ► Artikel lesen | |
| EVOTEC | 7,142 | +0,96 % | EQS-NVR: Evotec SE: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Gesamtstimmrechtsmitteilung: Evotec SE
/ Veröffentlichung der Gesamtzahl der Stimmrechte
Evotec SE: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG mit dem... ► Artikel lesen | |
| PURPLE BIOTECH | 0,980 | +67,67 % | Purple Biotech Ltd.: Purple Biotech Achieves Manufacturing Milestone for IM1240, a Tri-Specific Antibody from the CAPTN-3 Platform | Achieved commercially viable yield for IM1240, positioning the program competitively for future development Validates scalability of the CAPTN-3 tri-specific antibody platform IM1240, the first CAPTN-3... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 6,035 | +2,12 % | RECURSION PHARMACEUTICALS, INC. - 8-K, Current Report | ||
| 89BIO | 14,835 | 0,00 % | Roche Launches Tender Offer To Acquire 89bio For $14.50/shr Plus CVR | SOUTH SAN FRANCISCO (dpa-AFX) - Roche (RHHBY, RO.SW, ROG.SW) announced that it has launched a tender offer to acquire all outstanding common shares of 89bio, Inc. (ETNB). The offer includes... ► Artikel lesen | |
| NANOBIOTIX | 15,580 | +1,30 % | Nanobiotix S.A.: NANOBIOTIX Announces Updates to JNJ-1900 (NBTXR3) Clinical Program Following Transfer of Ongoing Phase 3 Head and Neck Cancer Trial Sponsorship and Operational Control | PARIS and CAMBRIDGE, Mass., Oct. 24, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO -- NASDAQ: NBTX - the "Company''), a late-stage clinical biotechnology company pioneering physics-based approaches... ► Artikel lesen | |
| BB BIOTECH | 44,200 | +0,57 % | EQS-Adhoc: BB BIOTECH AG: BB Biotech AG veröffentlicht Zwischenbericht | EQS-Ad-hoc: BB BIOTECH AG / Schlagwort(e): Zwischenbericht
BB Biotech AG veröffentlicht Zwischenbericht
24.10.2025 / 07:00 CET/CEST
Veröffentlichung einer Insiderinformation nach Artikel... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 24,500 | -2,04 % | Arcutis Biotherapeutics, Inc.: Arcutis Outlines Strategy for Driving Sustainable Growth and Announces Third Quarter 2025 Financial Results | Q3 2025 net product revenue for ZORYVE® (roflumilast) was $99.2 million, a 122% increase compared to Q3 of 2024, and a 22% increase compared to Q2 of 2025 ZORYVE cream 0.05% received U.S. Food and... ► Artikel lesen | |
| STRYKER | 319,30 | -1,05 % | Dividendenbekanntmachungen (30.09.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ACADIA REALTY TRUST US0042391096 0,2 USD 0,1705 EUR ADVANCED FLOWER CAPITAL INC US00109K1051 0,15 USD 0,1279 EUR AG MORTGAGE INVESTMENT... ► Artikel lesen | |
| AKEBIA | 1,980 | -3,98 % | Morning Market Movers: Cambium Networks, Stride, Inc., Varonis Systems, Akebia Therapeutics See Big Swings | CANBERA (dpa-AFX) - At 7:25 a.m. ET on Wednesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| DYNE THERAPEUTICS | 24,090 | -0,82 % | Why Dyne Therapeutics Stock Crushed the Market on Monday | ||
| VOR BIOPHARMA | 25,110 | -6,62 % | Vor Biopharma Inc. - 8-K, Current Report |